Evidence map›Paper›PMID 31264051›Full record

Trial reportJournal of molecular neuroscience : MN2019

Long Non-coding RNA BACE1-AS May Serve as an Alzheimer's Disease Blood-Based Biomarker.

Seyedeh Nahid Fotuhi, Mohammad Khalaj-Kondori, Mohammad Ali Hoseinpour Feizi, Mahnaz Talebi

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of molecular neuroscience : MN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 4 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. LncRNA BACE1-AS delays the propagation ofMicrobiology spectrum · 2025
    Article
  17. Review
  18. Review
  19. LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review.Cellular and molecular neurobiology · 2025
    Review
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Seyedeh Nahid FotuhiDepartment of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran.
Mohammad Khalaj-KondoriDepartment of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran. khalaj@tabrizu.ac.ir.ORCID http://orcid.org/0000-0001-9231-889X
Mohammad Ali Hoseinpour FeiziDepartment of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran.
Mahnaz TalebiNeurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
University of Tabriz · IRTabriz University of Medical Sciences · IR

Funding

Cognitive Sciences and Technologies Council 2717
6 · The paper itself

Abstract

Circulating long noncoding RNAs (lncRNAs) might serve as biomarkers for different pathological conditions. BACE1-AS lncRNA upregulates in the brain of people with Alzheimer's disease (AD) and might be detected in the bloodstream. To reveal if lncRNA BACE1-AS may serve as a blood-based biomarker for AD, we compared its levels in plasma and plasma-derived exosomes between AD (n = 45) and healthy people (n = 36). Exosomes were purified from plasma by Invitrogen™ Total Exosome Isolation Kit and characterized by scanning electron microscopy (SEM) and dynamic light scattering (DLS). Total RNA was extracted from whole plasma, and plasma-derived exosomes using TRIzol® LS or TRIzol® Reagents respectively were then reverse transcribed to the cDNA using PrimeScript II cDNA synthesis kit. The BACE1-AS levels were quantified by real-time PCR, and their biomarker potencies were evaluated using ROC curve analysis. Results obtained verified the presence of BACE1-AS in the plasma samples of both AD and healthy controls. We did not observe any significant differences between the levels of BACE1-AS in the plasma or plasma-derived exosomes of AD and control people. However, there were significant differences between AD subgroups and control in the whole plasma samples. The BACE1-AS level was low in pre-AD subgroup but it was high in full-AD people compared to the healthy controls. Moreover, ROC curve analysis revealed that lncRNA BACE1-AS may discriminate pre-AD and healthy control (75% sensitivity and 100% specificity), full-AD and healthy control (68% sensitivity and 100% specificity), and pre-AD and full-AD subgroups (78% sensitivity and 100% specificity), highlighting its potential as a biomarker for AD development. In conclusion, plasma BACE1-AS level may serve as a potent blood-based biomarker for Alzheimer's disease.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseApolipoproteins EBiomarkersExosomesFemaleHumansMaleMental Status and Dementia TestsMicroscopy, Electron, ScanningReal-Time Polymerase Chain ReactionRNARNA, Long NoncodingROC CurveSensitivity and SpecificityApolipoproteins EBACE1-AS long non-coding RNA, humanBiomarkersRNARNA, Long NoncodingAlzheimer’s diseaseBACE1-ASBiomarkerEarly detectionExosome

Identifiers

PMID31264051
OpenAlexW2953563476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.